Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Drug Industry's Real Post-Genomics Problem: Financing the Pipeline

This article was originally published in Start Up

Executive Summary

At iO Pharmaceuticals, two former Genentech executives aim to do for Big Pharma what Genentech, with its creative financing techniques, did for itself. By setting up a clinical development company, they plan to create off-P&L financing structures which will allow drug companies to develop more products without decreasing earnings.

You may also be interested in...



An Idea Too Good to Die

Drug companies always want to develop more drugs than they have funds for and a variety of companies have sprung up to offer financing alternatives for them. One company, Collabra, tried to take the enormously Genentech model and apply it to Big Pharma. It didn't work, and the reasons are instructive.

Paying for Pharmaceutical Value: The Problem of a One-Size-Fits-All Definition

It is a world, at least the US corner of it, in which any common understanding of drug value is confused by opposing incentives – to opacity and transparency, to looking at benefit broadly or narrowly, long-term or short-term: value, in short, to whom?

A Learning Lab For Outcomes-Based Risk-Sharing Agreements

Merck and UnitedHealth's Optum group have partnered to explore various value constructs.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC090297

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel